| Literature DB >> 28977199 |
Divyakant Parmar1, Ketav Lakhia2, Pankaj Garg2, Kartik Patel2, Ritesh Shah1, Jigar Surti1, Jigar Panchal1, Himani Pandya3.
Abstract
OBJECTIVE: The objective of our study was to determine the feasibility of early extubation and to identify the risk factors for delayed extubation in pediatric patients operated for ventricular septal defect closure.Entities:
Mesh:
Year: 2017 PMID: 28977199 PMCID: PMC5613723 DOI: 10.21470/1678-9741-2017-0031
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Demographic details.
| Group 1 ≤ 6 hrs (n=99) | Group 2 > 6 hrs (n=36) | ||
|---|---|---|---|
| Age (months) | 26.37 ± 30.89 | 18.5 ± 26.2 | 0.019 |
| Sex (male) | (56.56%) | (50%) | 0.7869 |
| Weight (kg) | 7.85 ± 4.14 | 6.38 ± 3.68 | 0.005 |
| Malnutrition | 88 (87.8%) | 32 (91.6%) | 0.808 |
| Trisomy 21 (n, %) | 2 (3%) | 7 (16.6%) | 0.015 |
| Type of VSD | |||
| Perimembranous (n, %) | 68 (68.6%) | 20 (55.5%) | 0.225 |
| Subaortic (n, %) | 19 (19.1%) | 10 (27.7%) | 0.402 |
| Muscular (n, %) | 12 (12.1%) | 6 (16.6%) | 0.688 |
| Size of VSD | |||
| Small VSD (n, %) | 24 (25.2%) | 7 (16.6%) | 0.802 |
| Moderate VSD (n, %) | 4 (4.04%) | __ | 0.533 |
| Large VSD (n, %) | 72 (70.7%) | 28 (83.3%) | 0.480 |
| PAH | |||
| Mild PAH (n, %) | 20 (21.21%) | 3 (5.5%) | 0.198 |
| Moderate PAH (n, %) | 10 (10.10%) | 3 (8.3%) | 0.931 |
| Severe PAH (n, %) | 70 (68.68%) | 29 (86.1%) | 0.208 |
| Lesions | |||
| Single VSD (n, %) | 80 (79.79%) | 23 (66.6%) | 0.139 |
| Multiple VSD (n, %) | 5 (5.05%) | 7 (19.4%) | 0.019 |
| VSD+PDA (n, %) | 3 (3.03%) | 1 (2.7%) | 0.618 |
| VSD+ASD (n, %) | 12 (12.12%) | 4 (11.1%) | 0.888 |
VSD=ventricular septal defect; ASD=atrial septal defect; PAH=pulmonary arterial hypertension; PDA=patent ductus arteriosus
Intraoperative and postoperative data.
| Group 1≤ 6 hrs (n=99) | Group 2> 6 hrs (n=36) | ||
|---|---|---|---|
| ACC time (min) | 28.45±11.18 | 31.30±14.91 | 0.443 |
| CPB time (min) | 46.75±13.84 | 50.91±19.53 | 0.522 |
| VIS | 9.01±2.05 | 10.65±2.94 | 0.001 |
| Arterial blood gas | |||
| pH | 7.38±0.04 | 7.38±0.07 | 0.937 |
| PCO2 (mmHg) | 38.29±5.78 | 38.20±7.9 | 0.978 |
| PO2 (mmHg) | 246.57±79.28 | 207.98±82.52 | 0.034 |
| Hematocrit (%) | 39.26±5.94 | 37.08±6.86 | 0.057 |
| Bicarbonate (mEq/L) | 26.24±24.82 | 22.85±3.12 | 0.893 |
| MVT (hours) | 4.4±0.9 | 25.9±24.9 | <0.001 |
| ICU stay (days) | 3.1±1.3 | 5.6±2.9 | <0.001 |
| Hospital stay (days) | 7.8±2.4 | 11.2±4.9 | <0.001 |
ACC=aortic cross-clamp; CPB=cardiopulmonary bypass; VIS=vasoactive inotropic score; PCO2=partial pressure of carbon dioxide; PO2=partial pressure of oxygen; MVT=mechanical ventilation time; ICU=intensive care unit
Postoperative complications and mortality.
| Group 1≤ 6 hrs (n=99) | Group 2>6 hrs (n=36) | ||
|---|---|---|---|
| Reintubation | 2 (2%) | 4 (11.1%) | 0.072 |
| LCOS | 0 | 6 (16.6%) | <0.001 |
| Heart block | |||
| Transient | __ | 3 | |
| Permanent | __ | __ | |
| Renal dysfunction | __ | __ | |
| Hepatic dysfunction | __ | __ | |
| Respiratory failure | __ | __ | |
| Haematological complication | __ | __ | |
| Prolonged mechanical ventilation | __ | __ | |
| Sepsis | 6 (6%) | 2 (5.5%) | 0.762 |
| Bleeding | __ | 1 (2.7%) | 0.596 |
| Neurological event | __ | 1 (2.7%) | 0.596 |
| Mortality | __ | 1 (2.7%) | 0.596 |
LCOS=low cardiac output syndrome
Regression analysis.
| Unstandardized coefficients | Standardized coefficients | 95% Confidence Interval for B | |||||
|---|---|---|---|---|---|---|---|
| B | Std. Error | Beta | t | Sig. | Lower bound | Upper bound | |
| (Constant) | 0.199 | 0.193 | 1.030 | 0.305 | -0.184 | 0.582 | |
| Age (month) | 0.003 | 0.003 | 0.200 | 1.164 | 0.247 | -0.002 | 0.008 |
| Weight | -0.028 | 0.019 | -0.261 | -1.526 | 0.130 | -0.065 | 0.008 |
| PO2 | -0.001 | 0.000 | -0.144 | -1.915 | 0.058 | -0.002 | 0.000 |
| Trisomy 21 | 0.438 | 0.133 | 0.248 | 3.303 | 0.001 | 0.176 | 0.701 |
| Multiple VSD | 0.376 | 0.116 | 0.243 | 3.240 | 0.002 | 0.147 | 0.606 |
| VIS | 0.032 | 0.015 | 0.174 | 2.090 | 0.039 | 0.002 | 0.062 |
| Transient HB | 0.211 | 0.267 | 0.071 | 0.790 | 0.431 | -0.318 | 0.740 |
| LCOS | 0.623 | 0.180 | 0.291 | 3.462 | 0.001 | 0.267 | 0.979 |
VSD=ventricular septal defect; PO2=partial pressure of oxygen; VIS=vasoactive inotropic score; HB=heart block; LCOS=low cardiac output syndrome
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ABG | = Arterial blood gases | MAP | = Mean arterial pressure | |
| ACC | = Aortic cross-clamp | PaCO2 | = Partial pressure of carbon dioxide | |
| ACT | = Activated clotting time | PAH | = Pulmonary arterial hypertension | |
| ASD | = Atrial septal defect | PDA | = Patent ductus arteriosus | |
| CPAP | = Continuous positive airway pressure | PEEP | = Peek end expiratory pressure | |
| CPB | = Cardiopulmonary bypass | PH | = Pulmonary hypertension | |
| ETCO2 | = End-tidal CO2 | PO2 | = Partial pressure of oxygen | |
| FiO2 | = Fraction of inspired oxygen | PTFE | = Polytetrafluroethylene | |
| ICU | = Intensive care unit | RHC | = Right heart catheterization | |
| IS | = Inotropic score | VIS | = Vasoactive inotropic score | |
| LCOS | = Low cardiac output syndrome | VSD | = Ventricular septal defect | |
| Authors' roles & responsibilities | |
|---|---|
| DP | Substantial contributions to the conception or design of the work; acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| KL | Revising the work critically for important intellectual content; final approval of the version to be published |
| PG | Substantial contributions to the conception or design of the work; acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| KP | Acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| RS | Substantial contributions to the conception or design of the work; final approval of the version to be publisheda |
| JS | Revising the work critically for important intellectual content; final approval of the version to be published |
| JP | Analysis, or interpretation of data for the work; final approval of the version to be published |
| HP | Interpretation of data for the work; final approval of the version to be published |